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ABSTRACT 
Objective: Curcumin (diferuloylmethane) is a a compound isolated from turmeric with biological activities, including antifertility. Curcumin inhibits 
COX-2 expression in granulosa cells of ovarian follicles and disrupts vascular endothelial growth factor (VEGF) derived angiogenesis in the 
endometrium, reducing endometrial receptivity. The purpose of this study was to examine the effects of curcumin on COX-2 and VEGF expression in 
endometrium of fertile women.  
Methods: A prospective double-blind placebo-controlled clinical trial was conducted in a group of fertile women with regular menstrual cycles, 
aged between 20-30 y, married, and with children. Subjects were divided into a group receiving daily 800 mg encapsulated curcumin. Curcumin 
orally for ten days, starting on the third day of the first menstrual day, and a control group. Endometrial biopsy was performed using a microcuret 
and immunohistochemistry was used to assess VEGF and COX-2 expression. The results were analysed using an independent sample t-test. 
Results: In the curcumin-treated group, VEGF expression was significantly lower than the control group (p<0.05), and COX-2 expression was higher 
but not significantly so (p>0.05). 
Conclusion: The curcumin causes VEGF expression in endometrium is lower and negatively affects the growth of endometrial stromal cells. 
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INTRODUCTION 
Curcumin (diferuloylmethane) is a polyphenol derived from the 
Curcuma longa plant, commonly called turmeric [1]. Curcumin has 
antifertility effects and may have applications in female contraception [2, 
3], and administration of intravaginal curcumin causes a reversible 
reduction in fertility [4]. In the endometrium, curcumin acts as a 
selective COX-2 inhibitor, where the administration of curcumin 100 
mg/kgBB on the first day of estrus until the fourth day after LH 
stimulation decreases COX-2 expression in the luminal epithelium and 
glandular endometrium, but does not reduce endometrial thickness or 
cell counts in the luminal epithelium in mice [8]. Meanwhile, vascular 
endothelial growth factor (VEGF) is a pro-angiogenic factor, produced in 
glands, endometrial stromal cells, and myometrial smooth muscle, 
whose expression increases in the late proliferation and endometrial 
secretory phases, resulting in an increase in endometrial vascularisation 
[5-7, 14, 15]. Decreasing the thickness of the endometrium will decrease 
the endometrial receptivity and thus inhibit the implantation process 
[10], and endometrial thickness can be used as an anatomical parameter 
to assess endometrial receptivity. 
Therefore, we hypothesised that dietary curcumin could lead to a 
decrease in fertility, as indicated by VEGF and COX-2 expression. We 
carried out a clinical trial to assess the effect of curcumin on the 
expression of VEGF and COX-2 in the endometrium at the middle of 
the menstrual cycle, using microcurets to assess endometrial 
thickness and Immunihistochemical expression VEGF and COX-2. 
MATERIALS AND METHODS 
We carried out a prospective phase III clinical trial study with a 
randomised double-blind placebo-controlled trial design [11, 12], at 
the Reproductive Health Clinic/Polyclinic of Central Hospital Dr. 
Zainoel Abidin, Banda Aceh, and the Rasi Clinic in Banda Aceh, 
between November 2012 to October 2014. Eighty fertile healthy 
women with a menstrual cycle of 26-28 d, aged between 20-30 y, 
and who had previously given birth were selected for a clinial trial. 
Women were excluded if they were using contraceptives, receiving 
hormonal therapy or treatments known to affect the menstrual 
cycle, or had a history of uterine tumours, unexplained vaginal 
bleeding, endometrial hyperplasia or endometrial thickness ≥ 14 
mm based on transvaginal ultrasound examination, galactorrhea, 
blood pressure above 160/95 mmHg or severe hypertension, acute 
or chronic pelvic infections, or pregnancy. All subjects were 
monitored for the duration of the trial. 
Forty women were randomly assigned to a treatment group was 
given 800 mg curcumin capsules orally beginning on the third day of 
menstruation for ten days, while the control group received a 
placebo. Immunocytochemistry examination of VEGF and COX-2 
expression was performed at the Anatomical Pathology Laboratory 
of the Faculty of Medicine University of Gajah Mada, Yogyakarta, 
Indonesia. An endometrial biopsy (microcuret) examination was 
carried out in the middle of the menstrual cycle. Patient in the 
lithotomy position at the gynecological table. Inserted Sim’s 
speculum into the vagina. Clean the portio with betadin, measure the 
depth of the uterine cavity with uterine sondase. Give local 
anesthesia (get 2% 4 cc) into the uterine cavity with a 5 cc syringe. A 
spoon curette no.1 inserted into the uterine cavity to take 
endometrial tissue. The tissue was inserted into a glass tube sample 
containing formalen buffer and the tube was closed tightly, then sent 
to the UGM Anatomy Pathology Laboratory, Yogyakarta, to produce 
Histopathological preparations and Immunocytochemistry l staining. 
Immunocytochemistry examination for COX-2 examination and 
VEGF expression. Data were analysed using an independent t-test, 
where difference were judged to be significant at p<0.05.  
RESULTS 
A comparison between curcumin treatment and a control group 
showed that mean VEGF/100 cell field of view expression. 
Histopathological preparations and immunocytochemistry staining 
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in VEGF expression in the curcumin group were calculate from 
epithelial surface, vascular endothelium and glandular. This group 
was significantly lower at 17.18±12.62 SD per 100 cells. compared 
with the control group at 42.78±32.94 SD per 100 cells (fig. 1, table I; 
p<0.05). Meanwhile, COX-2/100 cell expression was slightly higher 
in the curcumin group at 56.68±26.27 SD per 100 cells compared to 
44.43±31.82 SD per 100 cells in the control group, but this 
difference was not significant (fig. 2, table I; p>0.05). In the group 
that received curcumin, more cells expressed COX-2 on the epithelial 
surface, stroma and endometrial glands than controls (fig. 2). 
 
Table 1: VEGF and COX-2 expression calculated from stroma, cytoplasm and endometrial blood vessels in the middle of the menstrual cycle 
 
Expression 
Curcumin Control  
p n X ±SD n X ±SD 
VEGF (Σ/100 cells) 40 17.18±12.62 40 42.78±32.94 0.00 
COX-2 (Σ/100 cells) 40 56.68±26.27 40 44.43±31.82 0.06 




Fig. 1: Immunocytochemistry of VEGF expression on the surface, endothelium and gland after 10 d of curcumin administration. 
Endometrial gland cell morphology after Immunocytochemistry staining were characterised by the appearance of purple brown colour 
from chromogen diaminobenzidine tetrahydrochloride (DAB) in the cytoplasm, and the brown colour in the cytoplasm indicates the 
presence of VEGF expression. The cell nucleus appears round-oval and the blue/purple colour. Observations using a microscope phase 
contrast at 400 ×. VPT = High surface VEGF, VET = Endothelial VEGF High, VKT = High Gland VEGF, VPR = Low surface VEGF, VER = Low 
Endothelial VEGF, VKR = Low Gland VEGF. The arrows are appearance of Immunocytochemistry of VEGV expression 
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Fig. 2: Immunocytochemistry of COX-2 expression on the surface, endothelium and glands after 10 d of curcumin administration. The 
photomicroscopic image of endometrial gland cell morphology after Immunocytochemistry staining is characterised by the appearance of 
purple-brown colour from chromogen diaminobenzidine tetrahydrochloride (DAB) in the cytoplasm, indicating COX-2 expression. The 
cell nucleus looks round-oval and blue/purple. Observations were made using phase contrast microscopy with 400 × magnification. Low 
CKR = COX-2 Gland, Low Stroma CSR = COX-2, Low Surface CPR = COX-2, High CKT = COX-2 Gland, High Stroma CST = COX-2, High Surface 
CPT = COX-2. The arrows are appearance of Immunocytochemistry of COX-2 expression 
 
DISCUSSION 
The effect of curcumin on VEGF expression 
The amount of VEGF expression was lower in the curcumin group, 
indicating that curcumin has an antigonadotropic effect. VEGF 
targets endothelium to induce proliferation and migration for new 
blood vessels to grow and supply the endometrium, and works as a 
vasodilator by stimulating the release of prostacyclin and nitric 
oxide [24]. Curcumin suppresses VEGF secretion depending on the 
dose and reduces the growth of endometrial stromal cells, and 
induces apoptosis in endometrial epithelial cells [13]. Wieser et al. 
found that in an in vitro model of endometriosis, curcumin can 
decrease VEGF secretion and cell proliferation and induce apoptosis 
in normal cells and endometrium [13]. In normal endometrium, 
VEGF expression can be detected in both glandular and stromal 
epithelium, and expression in glandular cells increases 3-5 fold from 
the initial proliferation phase to the final secretion phase [16]. VEGF 
expression is at its highest in the middle of the secretion phase [17]. 
Macpherson et al. reported that immunoreactive VEGF significantly 
increased in the endometrial gland during the normal menstrual 
cycle [18]. In our study, VEGF levels were very low in the curcumin 
group, indicating that curcumin decreases VEGF expression in the 
final follicular phase. The results of this study indicate that there was 
a decrease in VEGF due to administration of curcumin. 
Rajuddin et al. 
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Effect of curcumin on COX-2 expression 
LH and FSH directly activate cAMP in granulosa preovulatory cells 
via the protein kinas A (PKA) pathway to increase the regulation of 
COX-2 expression [19, 20]. Similarly, LH can stimulate an increase in 
COX-2 expression [21]. In this study, the increased COX-2 expression 
in the curcumin group may indicate that the endometrium and 
granular cells may be different. Granulosa COX-2 expression cells are 
increase to the level of prostaglandin in ovarium after 24-36 h hCG 
administration [22]. Purwanti reported that COX-2 expression was 
highly increased in experimental animals treated with curcumin 
after LH stimulation compared to animals given curcumin with 
placebo[8]. An in vitro study conducted by Adiyanti et al. found that 
administration of curcumin at 100 mg/KgBW yielded a significant 
difference in increasing VEGF expression compared to a group 
treated with indomethacin, a non-selective COX inhibitor [9]. 
Meanwhile, curcumin is a selective COX-2 inhibitor, which stimulates 
apoptosis and angiogenesis inhibitors [8]. The presence of curcumin 
inhibitors such as COX-2 inhibitor during the adenylate cyclase and 
phospholipase pathway will reduce COX-2 expression [8]. 
Adenylate cyclase catalyses the formation of cAMP from ATP. cAMP 
stimulates the release of Ca2+from the endoplasmic reticulum and 
activates PKA. The released Ca2+binds to calmodulin and affects the 
activity of the COX-2 enzyme. Through the phospholipase pathway, 
active phospholipase will cause degradation of PIP2 
(Phatidylinositol bisphosphate) into IP3 (inositol 1,4,5 triphosphat), 
which stimulates the release of Ca2+ ions that bind to calmodulin, and 
DAG (Diacylglyserol), which activates protein kinase c (PKC). PKC 
and Ca2+
CONCLUSION 
binding with calmodulin will increase COX-2 [21]. Curcumin 
inhibits COX-2 expression in the follicular granulosa cells in the 
ovary, with the inhibition taking place prior to cAMP production 
[23]. Although our study indicated a moderate increase in COX-2 
under curcumin treatment, this was not significant, in contrast to 
our hypothesis. 
We found that curcumin reduces VEGF expression in the 
endometrium, but does not affect COX-2 expression. This study 
indicate that Curcumin is promising in acting as an antifertility or 
contraceptive agent. In the future, further research needs to be done, 
involving multicentres and large sample size with the aim of fertility 
regulation and antifertility treatment. This will strengthen the 
scientific basis for its use as fertility regulating drugs. 
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